| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2001;104:2057.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
From the William Dorros-Isadore Feuer Interventional Cardiovascular Disease Foundation Ltd, Grafton, Wis, Wilson, Wyo, and Phoenix, Ariz (G.D., A.M.D., L.M.M.); the Heart and Vascular Institute, Morristown, NJ (M.R.J.); and St Lukes Medical Center, Milwaukee, Wis (T.H.).
Reprint requests to Gerald Dorros, MD, FACC, Dorros-Feuer Foundation, 1331 N 7th St, Suite 215, Phoenix, AZ 85006. E-mail gdorros{at}dorrosfoundation.org
| Abstract |
|---|
|
|
|---|
Methods and Results TPVA was successful in 270 of 284 critically ischemic limbs (95%), with 167 limbs (59%) requiring dilatation of 333 ipsilateral inflow obstructions to access and successfully dilate 486 of 529 (92%) tibioperoneal lesions. A clinical success (relief of rest pain or improvement of lower-extremity blood flow) was attained in 270 limbs at risk (95%). Clinical 5-year follow-up of 215 of 221 successful CLI patients (97%) with 266 successfully revascularized limbs revealed that bypass surgery occurred in 8% and significant amputations in 9% of limbs; 91% of the limbs were salvaged. The cohorts probability of survival was 56%: 58% for Fontaine class III and 33% for class IV patients. Class III compared with class IV patients had significantly (P<0.05) fewer surgical bypasses (3% versus 16%) and amputations: above-knee, 1% versus 4%; below-knee, 3% versus 12%; and transmetatarsal, <1% versus 21%.
Conclusions TPVA, often in combination with inflow lesions, is an effective primary treatment for critical limb ischemia. The poor cumulative survival reflects the existence of severe comorbidities, which could potentially be affected by aggressive and effective cardiovascular diagnostic and therapeutic strategies.
Key Words: angioplasty peripheral vascular disease surgery vasculature
| Introduction |
|---|
|
|
|---|
| Methods |
|---|
|
|
|---|
Assessment Guidelines
Acute procedural success was defined as dilatation of the inflow lesion when present and critical lesion (
50% residual stenosis) and/or angiographic improvement in the distal collateral flow circumventing obstructed vessels by relief of a more proximal lesion(s). In-hospital success was defined by lack of surgical revascularization, abolition or amelioration of leg pain, a warm foot, a new distal pulse, and/or brisk arterial flow observed during wound debridement. Clinical follow-up assessed wound healing, the occurrence of surgical revascularization, amputation, and survival.
CLI Definitions
CLI was defined as (1) persistent, recurring rest pain requiring analgesia, and an ankle systolic pressure
50 mm Hg, and/or toe systolic pressure
30 mm Hg, and/or (2) ulceration, gangrene, or nonhealing wounds of the foot with ankle systolic pressure
50 mm Hg or toe systolic pressure
30 mm Hg. The Fontaine classification9 stratified patients as class III (rest pain) or class IV (ulceration and/or gangrene).
| Results |
|---|
|
|
|---|
|
|
|
|
|
Clinical 5-year follow-up on 215 of 221 CLI patients (97%) (Table 6) with 266 successfully revascularized limbs revealed that, by use of a hierarchical stratification, bypass surgery occurred in 8% and significant amputation in 9% of limbs. The probability of survival of the cohort (Figure 1) was 56%: 58% for class III and 33% for class IV patients (Figure 2). Class III compared with class IV patients had significantly (P<0.05) fewer surgical bypasses (3% versus 16%) and amputations: above-knee 1% versus 4%, below-knee 3% versus 12%, and transmetatarsal <1% versus 21%. Thus, salvage was attained in 91% of ischemic limbs. The event-free 5-year survival (freedom from death and any repeat vascular procedures) was 31% for the entire cohort (class III, 43% versus class IV, 26%; P<0.05).
|
|
|
| Discussion |
|---|
|
|
|---|
CLI Definitions
Although the definitions of CLI vary within the surgical literature, they all are relatively consistent with the definitions used here. The International Vascular Symposium Working Party10 defined severe rest pain as that which required opiate analgesia for
4 weeks, and either ankle pressure <40 mm Hg or ankle pressure <60 mm Hg in the presence of tissue necrosis or digital gangrene. The Modified International Vascular Symposium Working Party11 defined severe rest pain as that which required opiate analgesia for
4 weeks and either an ankle pressure <40 mm Hg or tissue necrosis or digital gangrene. The First European Working Group12 defined severe rest pain as that requiring opiate analgesia for
2 weeks, or ulceration or gangrene, or ankle pressures <50 mm Hg. The Second European Consensus Document13 defined persistently recurring ischemic rest pain as that which required analgesia for >2 weeks and an ankle systolic pressure <50 mm Hg, and/or a toe systolic pressure <30 mm Hg, or ulceration or gangrene of the foot or toes and an ankle systolic pressure <50 mm Hg, or toe systolic pressure <30 mm Hg.
Surgical Approaches
Femoropopliteal arterial reconstruction for infrainguinal peripheral arterial occlusive disease has better immediate and long-term results in patients with claudication than in those with CLI,14 and elective bypass surgery to the distal tibial vessels for intermittent claudication has had poor results. Thus, tibial artery bypass surgery to achieve revascularization distal to infrapopliteal obstructions has been reserved for selected CLI patients except in the presence of life-threatening sepsis (until resolved),15 flexion contractures or paralysis,16 patients with serious comorbid medical conditions, or patients with markedly reduced life expectancy. Although data on distal bypasses have not been encouraging, Veith and colleagues57,17 improved their distal bypass results by using innovative and creative techniques, which resulted in a dramatic decrease in their procedure-related amputation rates (49% to 14%). Their distal bypass procedures, however, had a coincident 30-day mortality of 4% and 90-day graft failure rates of nearly 5%. These data became the standard of care, with success defined as clinical improvement with resolution of rest pain. Yet, the problems of worsening graft patency as a result of distal anastomoses to small diseased vessels, diffuse distal arterial occlusive disease producing poor runoff (outflow), grafts crossing a joint, or graft composition (vein versus synthetic material)7,1820 make the use of percutaneous interventions even more attractive.
Curiously, not all patients whose first graft occluded required a second operation. Interestingly, the limb did not usually become rethreatened despite the original graft occlusion, and the wound did not recur after having healed. Such observations could be interpreted as indicating "surgical failure." If the therapeutic aim were to have a patent vessel, however, then graft closures would represent failure, but if the goal were to relieve rest pain or enable wound healing, then despite graft closure the procedure was successful. If this observation were extended to angioplasty, then lesion recurrence or restenosis might not be a major issue if the rest pain were no longer present or wound healing had occurred.
Surgical Results
Published longitudinal surgical data provided perspective to the usefulness of these TPVA data; 5 series will be detailed to show the similarities between the surgical and angioplasty data. A 2-year follow-up by the Italian census office of 522 CLI patients (394 men, 76%)21 detailed demographics of hypertension in 303 (58%), diabetes mellitus in 157 (30%), previous revascularization procedures in 113 (22%), prior myocardial infarction in 98 (19%), previous strokes in 54 (10%), and a lower limb amputation (30 [6%] major and 22 [4%] minor) in 52 (10%). Presenting symptoms included intermittent claudication in 449 patients (86%), rest pain in 200 (38%), and ischemic ulcers or gangrene in 322 (62%). This cohorts ABI revealed that 4% had an ABI >0.75; 6% an ABI 0.51 to 0.75; 61% an ABI 0.25 to 0.50; and 22% an ABI <0.25. Thus, the ABI was often not specific to severe ischemia. In the hospital, 232 patients (44%) had a revascularization procedure and 49 (10%) amputation (30 [6%] major and 22 [4%] minor), and after the procedure, 6 (1%) had a myocardial infarction and 8 (2%) had a stroke. During the first year of follow-up, 121 patients (22%) died: 44 (36%) of cardiovascular, 8 (7%) of nonvascular, and 69 (57%) of unknown causes. At 2 years, 30 patients had been lost to follow-up, and 44 of the remaining 401 patients had died (5.5% annualized mortality), with 13 (30%) of cardiovascular, 6 (14%) of nonvascular, and 25 (57%) of unknown causes; their cumulative probability of survival was 68%. Furthermore, data stratification demonstrated significant differences: a 22% mortality for patients <70 years old versus 42% for patients
70 years old; a 29% mortality for men versus 44% for women; a 53% mortality if the patient had a major amputation (53%) versus 30% if no major amputation occurred; a 28% mortality for Fontaine class III versus 55% for class IV patients; and a 37% mortality for diabetic versus 31% for nondiabetic patients. The independent 2-year mortality predictors were age
70 years (RR 1.93), prior stroke (RR 1.82), and major amputation (RR 1.90). These data are similar to the TPVA data shown here.
Holdsworth and McCollums22 3-year follow-up of 275 patients (116 women [51%]; mean age 72 years) with severe lower-limb ischemia involving 275 ischemic limbs revealed that rest pain was the clinical presentation in 168 limbs (61%), ulceration in 56 (20%), and gangrene in 51 (19%). Bilateral occlusive severe peripheral vascular disease was common, with 25 patients (11%) having had a previous contralateral limb amputation. The recorded ABIs were <0.40 in 158 patients (66%), <0.50 in 183 (74%), but
0.50 in 62 (26%), which again confirms the lack of specificity of the ABI. The therapeutic strategies included arterial reconstruction in 235 limbs (86%), primary amputation in 19 (7%), digital amputation in 6 (2%), and conservative management of 15 (6%). During the 3-year follow-up period, 100 patients had died (19 [8%] within 30 days of presentation, and 21 within 30 days of reconstruction [perioperative mortality of 10%]). The cumulative probability of survival was 69% at 1 year, 58% at 2 years, and 48% at 3 years, with causes of death not detailed. The cumulative probability of limb salvage was 94% at 30 days, 83% at 1 year, 73% at 2 years, and 68% at 3 years. Again, these data are comparable to those of TPVA.
Meyers et al23 reported on the survival after surgical treatment of 411 patients (249 men [60%]) with 468 severely ischemic limbs: one leg was ischemic in 354 patients and both legs in 57 patients. Surgical procedures included 273 reconstructions, 195 sympathectomies, and 128 amputations (27 primary and 101 after a failed reconstruction or sympathectomy). The operative mortality rates were significant: 5% for reconstruction or sympathectomy and 15% for major amputation. Survival probabilities were 80% at 1 year, 50% at 5 years, and 35% at 10 years. The 2-year survival rates correlated with the surgical procedure: 70% for arterial reconstruction, 60% for sympathectomy, and 55% for major amputation.
Wolfe and Wyatts24 collation of 20 lower-leg ischemia publications on 6118 patients stratified these patients into a low-risk cohort (4089 patients) (rest pain and ankle pressure >40 mm Hg) and a high-risk cohort (2029 patients) (rest pain and tissue loss [with or without ankle pressure <40 mm Hg]). The cumulative probability of survival for the entire group was 74% at 1 year, 58% at 2 years, 56% at 3 years, 48% at 4 years, and 44% for 5 years. At 1 year, if conservative treatments were used, 73% of the low-risk patients and 95% of the high-risk patients had lost their limb. When arterial reconstruction was performed on this high-risk group, the outcome resulted in a major amputation in 25%, and 26% of this group would be dead no matter what the treatment.
Finally, a 69-site European registry25 followed up 574 patients (431 men, 75%; mean age 71 years), of whom 485 (87.5%) had rest pain and 352 (64%) had ulcers or gangrene. Surgical management included arterial reconstruction in 195 (34%) and sympathectomy in 55 (10%); a major amputation was necessary in 53 patients (9%), a minor amputation in 30 patients (5%), thromboendarterectomy in 44 (8%), angioplasty in 41 (7%), and epidural spinal electrostimulation in 22 (4%). At the 3-month follow-up, 50 patients had died (9%), and 286 patients (50%) were alive, had no ischemic limb, and had not endured any major cardiovascular event; 103 patients (18%) were alive but had persistent CLI, 70 patients (12%) were alive but had endured a major amputation, and 9 patients (2%) were alive but had suffered an infarction or stroke and still had persistent limb ischemia. Thus, surgical reconstruction can be achieved in patients with CLI, but at the cost of significant morbidity and mortality.
Angioplasty Results
These TPVA data demonstrate revascularization success rates (94%) similar if not superior to those in recent publications.2631 These studies must be looked at carefully, however, because the definitions of CLI were often indistinct. Not unexpectedly, TPV disease was often (59% of limbs) preceded by inflow lesion angioplasty so as to gain access to the obstructed tibioperoneal vessels. The patients of Lofberg et al31 required this approach in 55 of 94 procedures (59%). The successful inflow lesion angioplasty markedly improved the distal perfusion pressure (as would be attained by femoropopliteal bypass), but in addition, the distal perfusion pressure to the ischemic foot was enhanced by angioplasty of the outflow lesion, not readily achieved with surgery. At 5-year follow-up, 91% of limbs were salvaged, which is significantly higher than and in sharp contrast to those reported, because follow-up extended for 2 years (89%,26 49%,27 80%,28 87%29), and rarely 3 years (87%,26 72%28). The 5-year survival statistics were sobering, with only a 56% survival; and these values were supported by the 76% 2-year26 and the 75% 3-year29 survivals. These TPVA data, with similar patient demographics, and the impressive procedural success demonstrate that this interventional technique is an important therapeutic option. The TPVA procedural and follow-up results were superior to those of the historical surgical series; the differences in endovascular and surgical survival rates, however, are even more dramatic when the surgical procedural operative mortality is considered. Endovascular procedures offer a significant alternative to surgical procedures.
Conclusions
Endovascular therapy has an important and definitive role for patients with infrapopliteal arterial occlusive disease and CLI by easily revascularizing inflow and outflow lesions with minimal morbidity and mortality, which significantly improved distal extremity perfusion pressure. This more complete restoration of blood flow than can be attained by bypass surgery in the presence of the outflow lesions resulted in immediate relief of rest pain and enhancement of wound healing, often in conjunction with transmetatarsal amputation. TPVA produced improved patient outcomes, and the 5-year follow-up data showed that the need for subsequent surgical bypass or amputation was acceptable considering the patient populations. Although the survival statistics were sobering, they direct us toward the need for much more aggressive diagnostic and therapeutic approaches for these patients. These patients have advanced, diffuse coronary heart and/or cerebrovascular disease. This issue requires our immediate attention. This communication raises other issues that must be addressed: is stent-supported angioplasty with or without adjunctive use of glycoprotein inhibitors superior to balloon angioplasty? Does brachytherapy have a therapeutic role, especially with regard to restenosis? These data, however, provide evidence that angioplasty is the primary therapy for patients with CLI.
| Acknowledgments |
|---|
Received February 27, 2001; revision received August 15, 2001; accepted August 17, 2001.
| References |
|---|
|
|
|---|
2.
Brown KT, Schoenberg NY, Moore ED, et al. Percutaneous transluminal angioplasty of infrapopliteal vessels: preliminary results and technical considerations. Radiology. 1988; 169: 7578.
3. Schwarten DE. Clinical and anatomical considerations for nonoperative therapy in tibial disease and the results of angioplasty. Circulation. 1991; 83: 186190.
4. Second European consensus document on chronic critical leg ischemia. Circulation. 1991; 84 (suppl IV): IV-1IV-26.
5. Veith FJ, Gupta SK, Ascer E, et al. Improved strategies for secondary operations on infrainguinal arteries. Ann Vasc Surg. 1990; 4: 8593.[Medline] [Order article via Infotrieve]
6. Ascer E, Collier P, Gupta SK, et al. Reoperation for polytetrafluoroethylene bypass failure: the importance of distal outflow site and operative technique in determining outcome. J Vasc Surg. 1987; 5: 298310.[Medline] [Order article via Infotrieve]
7. Veith FJ, Gupta SK, Wengerter KR, et al. Changing arteriosclerotic disease patterns and management strategies in lower-limb threatening ischemia. Ann Surg. 1990; 212: 402414.[Medline] [Order article via Infotrieve]
8. Dorros G, Jaff MR, Kelly KJ, et al. The acute outcome of tibioperoneal vessel angioplasty in 417 cases with claudication and critical limb ischemia. Cathet Cardiovasc Diagn. 1998; 45: 251256.[Medline] [Order article via Infotrieve]
9. Fontaine R, Kim M, Kieny R. Die chirugische Behandlung der peripheren Durchblutungsstörungen. Helv Chir Acta. 1954; 21: 499.
10. Bell PRF, Charlesworth D, De Palma RG, et al. The definition of critical ischemia of a limb. Br J Surg. 1982; 69 (suppl): 52.[Medline] [Order article via Infotrieve]
11. Tyrrell MR, Wolfe JHN. Critical leg ischemia: an appraisal of clinical definitions. Br J Surg. 1993; 80: 177180.[Medline] [Order article via Infotrieve]
12. European consensus on critical limb ischaemia. Lancet. 1989; 1: 737738.
13. Second European consensus document on chronic critical leg ischaemia. Eur J Vasc Surg. 1992; 6 (suppl A): 132.
14. Veith FJ, Gupta SK, Samson RH, et al. Progress in limb salvage by reconstructive arterial surgery combined with new or improved adjunctive procedures. Ann Surg. 1981; 194: 386401.[Medline] [Order article via Infotrieve]
15. Walsh DB, Gilbertson JJ, Zwolak RM, et al. The natural history of superficial femoral artery stenoses. J Vasc Surg. 1991; 14: 299304.[Medline] [Order article via Infotrieve]
16.
McIntyre KE Jr, Bailey SA, Malone JM, et al. Guillotine amputation in the treatment of non-salvageable lower extremity infections. Arch Surg. 1984; 119: 450453.
17. Veith FJ, Gupta SK, Daly V. Management of early and late thrombosis of expanded polytetrafluoroethylene (PTFE) femoropopliteal bypass grafts: favorable prognosis with appropriate reoperation. Surgery. 1980; 87: 581587.[Medline] [Order article via Infotrieve]
18. AbuRahma AF, Woodruff BA, Lucente FC. Edema after femoropopliteal bypass surgery: lymphatic and venous theories of causation. J Vasc Surg. 1990; 11: 461467.[Medline] [Order article via Infotrieve]
19. Veith FJ, Gupta SK, Ascer E, et al. Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. J Vasc Surg. 1986; 3: 104114.[Medline] [Order article via Infotrieve]
20. Hobson RWII, Lynch TG, Jamil Z, et al. Results of revascularization and amputation in severe lower extremity ischemia: a five-year clinical experience. J Vasc Surg. 1985; 2: 174185.[Medline] [Order article via Infotrieve]
21. The I.C.A.I. Group (Gruppo di Studio dellIschemia Cronica Critica degli Arti Inferiori). Long-term mortality and its predictors in patients with critical leg ischaemia. The Study Group of Critical Chronic Ischemia of the Lower Extremities. Eur J Vasc Endovasc Surg. 1997; 14: 9195.[Medline] [Order article via Infotrieve]
22. Holdsworth RJ, McCollum PT. Results and resource implications of treating end-stage limb ischaemia. Eur J Endovasc Surg. 1997; 13: 164173.
23. Meyers KA, King RB, Scott DF, et al. Survival treatment of the severely ischemic leg: survival rates. Br J Surg. 1978; 65: 460464.[Medline] [Order article via Infotrieve]
24. Wolfe JHN, Wyatt MG. Critical and subcritical ischemia. Eur J Vasc Endovasc Surg. 1997; 13: 578582.[Medline] [Order article via Infotrieve]
25. I.C.A.I Group. A prospective epidemiological survey of the natural history of chronic critical limb ischemia. Eur J Vasc Endovasc Surg. 1996; 11: 112120.[Medline] [Order article via Infotrieve]
26. London NJ, Varty K, Sayers RD, et al. Percutaneous transluminal angioplasty for lower-limb critical ischaemia. Br J Surg. 1995; 82: 12321235.[Medline] [Order article via Infotrieve]
27. Matsi P. Percutaneous transluminal angioplasty in critical limb ischaemia. Ann Chir Gynaecol. 1995; 84: 359362.[Medline] [Order article via Infotrieve]
28. Soder HK, Manninen HI, Jaakkola P, et al. Prospective trial of infrapopliteal artery balloon angioplasty for critical limb ischemia: angiographic and clinical results. J Vasc Interv Radiol. 2000; 11: 10211031.[Medline] [Order article via Infotrieve]
29. Boyer L, Therre T, Garcier JM, et al. Infrapopliteal percutaneous transluminal angioplasty for limb salvage. Acta Radiol. 2000; 41: 7377.[Medline] [Order article via Infotrieve]
30. Brillu C, Picquet J, Villapadierna F, et al. Percutaneous transluminal angioplasty for management of critical limb ischemia in arteries below the knee. Ann Vasc Surg. 2001; 15: 175181.[Medline] [Order article via Infotrieve]
31. Lofberg AM, Lorelius LE, Karacagil S, et al. The use of below-knee percutaneous transluminal angioplasty in arterial occlusive disease causing chronic critical limb ischemia. Cardiovasc Intervent Radiol. 1996; 19: 317322.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
P. Balaz, S. Rokosny, B. Koznar, and M. Adamec Combined infrainguinal reconstruction and infrapopliteal intraluminal angioplasty for limb salvage in critical limb ischemia Interactive CardioVascular and Thoracic Surgery, August 1, 2009; 9(2): 191 - 194. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Cremonesi, N. Diehm, A. Stella, M. Gargiulo, G. Faggioli, E.#x.;v.;o C. de Campos Martins, and F. Castriota CHAPTER 36 Peripheral Arterial Occlusive Disease ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A Arain and C. J White Endovascular therapy for critical limb ischemia Vascular Medicine, August 1, 2008; 13(3): 267 - 279. [Abstract] [PDF] |
||||
![]() |
D. P. Slovut and T. M Sullivan Critical limb ischemia: medical and surgical management Vascular Medicine, August 1, 2008; 13(3): 281 - 291. [Abstract] [PDF] |
||||
![]() |
A. J. Feiring Footnotes on Critical Limb Ischemia J. Am. Coll. Cardiol., May 20, 2008; 51(20): 1975 - 1976. [Full Text] [PDF] |
||||
![]() |
E. Ascher, A. P. Hingorani, and N. Marks Duplex-Guided Balloon Angioplasty of Lower Extremity Arteries Perspectives in Vascular Surgery and Endovascular Therapy, March 1, 2007; 19(1): 23 - 31. [Abstract] [PDF] |
||||
![]() |
J. Emmerich Current State and Perspective on Medical Treatment of Critical Leg Ischemia: Gene and Cell Therapy International Journal of Lower Extremity Wounds, December 1, 2005; 4(4): 234 - 241. [Abstract] [PDF] |
||||
![]() |
P. Huang, S. Li, M. Han, Z. Xiao, R. Yang, and Z. C. Han Autologous Transplantation of Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood Mononuclear Cells Improves Critical Limb Ischemia in Diabetes Diabetes Care, September 1, 2005; 28(9): 2155 - 2160. [Abstract] [Full Text] [PDF] |
||||
![]() |
D Tsetis and A-M Belli The role of infrapopliteal angioplasty Br. J. Radiol., December 1, 2004; 77(924): 1007 - 1015. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Bettmann, M. D. Dake, L. N. Hopkins, B. T. Katzen, C. J. White, A. C. Eisenhauer, W. H. Pearce, K. A. Rosenfield, R. W. Smalling, T. A. Sos, et al. Atherosclerotic Vascular Disease Conference: Writing Group VI: Revascularization Circulation, June 1, 2004; 109(21): 2643 - 2650. [Full Text] [PDF] |
||||
![]() |
S. W. Stavropoulos, J. A. Solomon, M. C. Soulen, T. W. I. Clark, and R. D. Shlansky-Goldberg Use of Abciximab during Infrainguinal Peripheral Vascular Interventions: Initial Experience Radiology, June 1, 2003; 227(3): 657 - 661. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Tefera, W. Turnipseed, and T. Tanke Limb Salvage Angioplasty in Poor Surgical Candidates Vascular and Endovascular Surgery, March 1, 2003; 37(2): 99 - 104. [Abstract] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |